Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

Lynda M. Vrooman; Traci M. Blonquist; Kristen E. Stevenson; Jeffrey G. Supko; Sarah K. Hunt; Sarah M. Cronholm; Victoria Koch; Samantha Kay‐Green; Uma H. Athale; Luis A. Clavell; Peter D. Cole; Marian H. Harris; Kara M. Kelly; Caroline Laverdière; Jean‐Marie Leclerc; Bruno Michon; Andrew E. Place; Marshall A. Schorin; Jennifer Welch; Donna Neuberg; Stephen E. Sallan; Lewis B. Silverman

doi:10.1200/jco.20.03692

Abstract

This is the authors' abstract. We don't add key points for this paper.

Every 3-week calaspargase had similar nadir SAA, toxicity, and survival outcomes compared with every 2-week pegaspargase. The high nadir SAA observed for both preparations suggest dosing strategies can be further optimized.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vrooman et al. (2021) studied this question.

synapsesocial.com/papers/69d8e82833ca018b39ae44eb https://doi.org/10.1200/jco.20.03692

View at Publisher

Ask AI

Bookmark

Share

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

Abstract

Ask about this paper

Discussion

Cite This Study

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading